Auxilium Pharmaceuticals Presents Interim Data on XIAFLEX for Retreatment of Recurring Dupuytren's Contracture
January 08, 2014 at 07:01 AM EST
Auxilium Pharmaceuticals (NASDAQ: AUXL ) today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX® (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture (DC) and a recurrent contracture with a palpable cord will be presented for the first time at the American